ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 –...
Pregnancy
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
BodiGuide Inc. Announces Technology Breakthrough; Revolutionary New Device Continuously Measures Edema
From Heart Failure to Kidney Disease, Patients with Chronic Conditions Will Automatically Inform Their Healthcare Provider About Treatment EfficacyBELLEVUE, Wash.,...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12...
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC)...
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 -...
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE)...
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
--FemaSeed® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- --Company remains on...
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating...
Albireo Announces 2022 SPARK Grant Winners
— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in...
Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
Clinical cure rates, in the pooled analysis, were statistically significantly greater for ibrexafungerp when compared with placebo (p < 0.0001).In...
ICSI outcomes unchanged in men with normal or abnormal Cap-Scores™
ICSI fertilization rates and subsequent pregnancy rates were not different between men with normal or low Cap-ScoresMen with low Cap-Scores...
The Cap-Score™ is a more sensitive indicator of male fertility across age groups than traditional semen analysis
New study demonstrates the value of using the Cap-Score Test to assess the fertilizing ability in men of all ages...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and...
Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm...
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in...